EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli

The receptor tyrosine kinases (RTKs) family is well-recognized as vital targets for the treatment of hepatocarcinoma cancer (HCC) clinically, whereas the survival benefit of target therapy sorafenib is not satisfactory for liver cancer patients due to metastasis. EGFR and MET are two molecules of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Shouyang, Yu, Zhen, You, Yajing, Liu, Chenxi, Xie, Xiaoyu, Lv, Huanran, Xiao, Feng, Zhu, Qiang, Qin, Chengyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012802/
https://www.ncbi.nlm.nih.gov/pubmed/35428350
http://dx.doi.org/10.1038/s41419-022-04796-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012802/
https://www.ncbi.nlm.nih.gov/pubmed/35428350
http://dx.doi.org/10.1038/s41419-022-04796-8

Ejemplares similares